QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
NASDAQ:TPTX

Turning Point Therapeutics Stock Forecast, Price & News

$35.93
-0.61 (-1.67%)
(As of 01/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$35.77
▼
$39.19
50-Day Range
$35.02
▼
$51.25
52-Week Range
$34.16
▼
$141.30
Volume
224,915 shs
Average Volume
502,870 shs
Market Capitalization
$1.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.88
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Turning Point Therapeutics logo

About Turning Point Therapeutics

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

Headlines

Turning Point Gets FDA OK for Elzovantinib/Aumolertinib Combo Study >TPTX
January 20, 2022 |  marketwatch.com
FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting
January 20, 2022 |  msn.com
FDA clears Turning Point Investigation New Drug application for NSCLC combination
January 20, 2022 |  seekingalpha.com
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer
January 20, 2022 |  finance.yahoo.com
Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones
January 18, 2022 |  finance.yahoo.com
Turning Point Therapeutics (NASDAQ:TPTX) Sets New 12-Month Low at $34.39
January 14, 2022 |  americanbankingnews.com
Turning Point Therapeutics Inc Shares Near 52-Week Low - Market Mover
January 14, 2022 |  nasdaq.com
Hedge Funds Aren’t Crazy About Turning Point Therapeutics, Inc. (TPTX) Anymore
January 12, 2022 |  finance.yahoo.com
Turning Point Therapeutics (NASDAQ:TPTX) Stock Price Down 5.2%
January 12, 2022 |  americanbankingnews.com
Turning Point Therapeutics (NASDAQ:TPTX) Shares Gap Down to $49.80
December 28, 2021 |  americanbankingnews.com
Interesting TPTX Put And Call Options For February 2022
December 20, 2021 |  nasdaq.com
Turning Point Therapeutics Provides Regulatory Updates
December 20, 2021 |  finance.yahoo.com
Should I Buy Nektar Therapeutics (NKTR)?
December 13, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TPTX
Previous Symbol
CUSIP
N/A
CIK
1595893
Web
www.tptherapeutics.com
Phone
(858) 926-5251
Fax
N/A
Employees
142
Year Founded
N/A

Sales & Book Value

Annual Sales
$25 million
Price / Sales
71.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$23.04 per share
Price / Book
1.56

Profitability

EPS (Most Recent Fiscal Year)
($4.23)
Net Income
$-157.29 million
Net Margins
N/A
Pretax Margin
-666.51%
Return on Equity
-19.13%
Return on Assets
-18.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
27.02
Quick Ratio
27.02

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
49,480,000
Free Float
45,868,000
Market Cap
$1.78 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/20/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.94 out of 5 stars

Medical Sector

692nd out of 1,418 stocks

Pharmaceutical Preparations Industry

337th out of 683 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

Is Turning Point Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics or view top-rated stocks.

How has Turning Point Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TPTX shares have decreased by 11.4% and is now trading at $35.93.
View which stocks have been most impacted by COVID-19.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Turning Point Therapeutics.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.26) by $0.08. The business earned $0.46 million during the quarter. During the same period last year, the firm earned ($0.42) EPS.
View Turning Point Therapeutics' earnings history.

What price target have analysts set for TPTX?

9 brokers have issued 1 year price objectives for Turning Point Therapeutics' shares. Their forecasts range from $75.00 to $175.00. On average, they expect Turning Point Therapeutics' share price to reach $125.57 in the next twelve months. This suggests a possible upside of 249.5% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:
  • Athena Countouriotis, President, Chief Executive Officer & Director
  • Miriam Cruz, Vice President-Clinical Operations
  • Paolo Tombesi, Executive VP, Chief Financial & Accounting Officer
  • Siegfried Reich, Chief Scientific Officer & Executive VP (LinkedIn Profile)
  • Ed Gemo, Chief Information Officer & Senior Vice President

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.72%), Stonnington Group LLC (0.07%), Lindbrook Capital LLC (0.00%) and Cutler Group LP (0.00%). Company insiders that own Turning Point Therapeutics stock include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mark J Alles, Mohammad Hirmand, Siegfried Reich and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics.

Which institutional investors are buying Turning Point Therapeutics stock?

TPTX stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Stonnington Group LLC, Lindbrook Capital LLC, and Cutler Group LP. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, and Mark J Alles.
View insider buying and selling activity for Turning Point Therapeutics or or view top insider-buying stocks.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $35.93.

How much money does Turning Point Therapeutics make?

Turning Point Therapeutics has a market capitalization of $1.78 billion and generates $25 million in revenue each year. The company earns $-157.29 million in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does Turning Point Therapeutics have?

Turning Point Therapeutics employs 142 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Where are Turning Point Therapeutics' headquarters?

Turning Point Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 926-5251 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.